Atossa Therapeutics, Inc. (ATOS)
After hours:
| Previous close | 1.6300 |
| Open | 1.6400 |
| Bid | 1.5200 x 1200 |
| Ask | 1.5500 x 1200 |
| Day's range | 1.5105 - 1.6400 |
| 52-week range | 0.6200 - 2.3100 |
| Volume | |
| Avg. volume | 1,956,393 |
| Market cap | 192.408M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2400 |
| Earnings date | 12 Aug 2024 - 16 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.33 |
ZacksAtossa Genetics Inc. (ATOS) is a Great Momentum Stock: Should You Buy?
Does Atossa Genetics Inc. (ATOS) have what it takes to be a top stock pick for momentum investors? Let's find out.
GlobeNewswireAtossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial
SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the last patient in the Company’s Karisma-Endoxifen clinical trial received their final dose of study medication. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. The Karisma-Endoxifen study, which fully enrolled in November 2023, is a 240-person
- GlobeNewswire
Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
Presented data from EVANGELINE study showing 100% disease control rate at 24-weeks Initiated study evaluating (Z)-endoxifen in combination with abemaciclib (VERZENIO®)Ended first quarter 2024 with $84.0 million of cash and cash equivalents and no debt SEATTLE, May 13, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced financial results for the fiscal quarter ended March 31, 2024, and provides an update on recent company developments. Ato
